| Disease | A DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED TRIAL IN AN OUTPATIENT LIPID RESEARCH CLINIC WAS PERFORMED AND INCLUDED 50 MODERATELY HYPERCHOLESTEROLEMIC SUBJECTS(MEAN LDL CHOLESTEROL = 166 DL 22 MG/DL) CLASSIFIED AS LDL SUBCLASS PATTERN A
(PREDOMINANTLY LARGE LDL, N = 22) OR B(PREDOMINANTLY SMALL LDL, N = 28). FOLLOWING A 2-MONTH STABILIZATION PERIOD, SUBJECTS WERE RANDOMLY ASSIGNED TO A PLACEBO OR 300 MG 3 TIMES A DAY OF A STANDARDIZED GARLIC TABLET FOR THREE MONTHS. FOR ALL
SUBJECTS, LDL PATTERN A AND B SUBJECTS COMBINED, GARLIC TREATMENT FOR 3 MONTHS RESULTED IN NO SIGNIFICANT CHANGE IN TOTAL CHOLESGTEROL, LDL CHOLESTEROL, HDL CHOLESTEROL, HDL SUBCLASS DISTRIBUTION, POSTPRANDIAL TRIGLYCERIDES, APOLIPOPROTEIN B,
LIPOPROTEIN (A)(LP[A]), LDL PEAK PARTICLE DIAMETER OR LDL SUBCLASS DISTRIBUTION. THERE WAS NO SIGNIFICANT DIFFERENCE IN RESPONSE FOR THE SAME PARAMETER AMONG SUBJECTS CLASSIFIED AS LDL PATTERN A OR B WITH THE EXCEPTION OF SIGNIFICANTLY GREATER
(P = 0.01) REDUCTION IN MEAN PEAK PARTICLE DIAMETER IN PATTERN A SUBJECTS TREATED WITH EITHER GARLIC OR PLACEBO. THERE WAS NO SIGNIFICANT CHANGE IN LDL SUBCLASS DISTRIBUTION. THIS INVESTIGATION CONFIRMS THAT GARLIC THERAPY HAS NO EFFECT ON MAJOR
PLASMA LIPOPROTEINS AND FURTHER, THAT IT HAS NO IMPACT ON HDL SUBCLASS, LP(A), APOLIPOPROTEIN B, POSTPRANDIAL TRIGLYCERIDES OR LDL SUBCLASS DISTRIBUTION. GARLIC MAY HAVE A GREATER EFFECT ON LDL PARTICLE DIAMETER IN LDL PATTERN A COMPARED WITH
PATTERN B SUBJECTS. THIS DIFFERENCE WAS NOT REFLECTED IN OTHER PLASMA LIPID MEASUREMENTS.
A COMMERCIAL PRODUCT, KWAI, WAS USED. |